NCT05216562 - Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

December 30, 2022

Conditions

SARS-CoV2 Infection

Interventions

DRUG

Exosome-MSC Intravenous injection

Intravenous injection of Exosome-MSC

DRUG

Placebo Intravenous Injection

Intravenous injection of Placebo

DRUG

COVID-19 Standard Treatment

Specific drugs considered standard treatment for COVID-10 by each location may vary

Trial Locations (3)

RECRUITING

RSPAD Gatot Soebroto, Jakarta

RECRUITING

RSUP Dr. M. Jamil, Padang

RECRUITING

RSUP Dr. Sardjito, Yogyakarta